However, there exists a gridlock that obstructs these cancer therapies to be become an integral part of modern-day personalized therapy [17, 18] . With the 67 advancement of data-driven approaches [19, 20] , the concept behind 'one-drug-one-68 target' has changed. The response outcome of a drug depends on many factors, such 69 as mutations, compensatory mechanisms, epigenetics, dysregulated genes and many 70 more, making a prediction of drug's efficacy a real challenge for decades. These 71 regulatory factors either could be in the immediate vicinity of drug's mechanism of 72 action (MoA) or could be trans-regulatory that acts by modulating relevant genes' 73 expression. These down-streams effects (i.e. gene's up or down-regulations) are easy 74 to assess and can directly be linked to pathways or cellular processes, thereby, giving 75 an answer to how and why a patient could be sensitive to a given therapy [21] . The 76 advantage of such a data-driven approach is that it is free from any pre-conceptualized 77 bias like drug targets, disease genes etc.
78
However, dealing with the enormous amount of gene expression data is both 79 time and computation expensive. There is a sheer need for a rapid and robust method 80 for biomarker identification which can lead to stratify patients as per their response to 81 the drug. In this study, transcriptomic data has been analyzed through a machine 82 learning pipeline which has been developed for rapid identification of drug response 83 biomarkers and thereafter patient stratification.
84
The work has used the data from the experiment submitted to NCBI GEO as 
257
The identified potential biomarkers with their weights have been given in 
Functional analysis:
Identified genes that could predict the response of 278 samples to the drug, could be used as potential drug response biomarkers.
279
Hence it was required to understand their link to drug's mechanism of action. to Imatinib response is yet to be validated. 
Network analysis

337
As was mentioned earlier, it is essential to know the regulatory link between 338 identified genes and drug's MoA or drug's direct targets. To address this, BN 339 was created for responders and non-responders, followed by comparison 340 between two networks (Fig. 5A-C) . The network architecture for responder 341 samples (Fig. 5A ) differed significantly from that of non-responder samples 342 (Fig. 5B) . The comparative figure (Fig. 5C) showed new connection that 
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Blue dashed lines appear in non-responders while red lines disappear in them.
349
Black lines remain unchanged in both cases. 
